New Delhi, April 4 – India’s drug regulators are increasing their oversight of rapidly growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.This move comes as the...
New Delhi, March 17 – The Delhi High Court issued a notice on Tuesday regarding a contempt petition alleging non-compliance with its earlier order directing the Central Drugs Standard Control Organisation (CDSCO) to examine safety and regulatory concerns regarding the use of certain diabetes...
cdsco
central drugs standard control organisation
contempt petition
dcgi
delhi high court
diabetes drugs
drugs controller general of india
glp-1receptoragonists
judicial directions
legal proceedings
new drugs and clinical trials rules
pharmacovigilance
regulatory compliance
union health secretary
weight loss
New Delhi, March 17 Fake and falsified obesity drugs could be prompting a public health concern driven by high prices, a lack of insurance, and the desire to lose weight, according to a world report article published in The Lancet journal.Author Sophie Cousins, an Australian writer and health...
cardiovascular health
counterfeit drugs
diabetes treatment
drug safety
fda warning
glp-1receptoragonists
mexico
mounjaro
obesity drugs
ozempic
pharmaceutical fraud
prescription drugs
public health
united states
weight loss
world health organization
New Delhi, February 27 Drug maker Abbott announced on Friday that it has partnered with Novo Nordisk India to commercialize Extensior, a second brand of Ozempic, for the treatment of type 2 diabetes in the country.The partnership leverages Novo Nordisk's scientific leadership in GLP-1s and...